Key Takeaways
- The company reported a fourth-quarter net loss of €305 million, a stark reversal from the previous year’s €259.5 million profit
- 2026 revenue projections of €2–2.3 billion fell significantly short of analyst estimates of €2.75 billion
- Founding CEO Ugur Sahin and CMO Ozlem Tureci plan to depart by December to establish a new biotech enterprise
- The German firm will provide mRNA technology to the founders’ new company in return for an equity position and future royalties
- Declining demand for Covid-19 vaccines in U.S. and European markets is driving revenue expectations lower for 2026
BioNTech shareholders faced a challenging Tuesday as the company delivered three consecutive pieces of disappointing news — disappointing quarterly results, underwhelming forward guidance, and an unexpected leadership transition. Shares plummeted 17% during premarket hours, marking the steepest intraday decline for BNTX since December 2021.
The German pharmaceutical company disclosed a fourth-quarter net loss of €305 million, representing a significant swing from the €259.5 million profit recorded during the comparable period last year. Quarterly revenue totaled €907.4 million, reflecting a decrease from the prior year’s €1.19 billion.
When calculated on a per-share basis, BioNTech’s fourth-quarter loss reached €1.25. This figure substantially exceeded the analyst consensus of a €0.45 loss, representing a meaningful departure from expectations.
The forward-looking guidance proved even more troubling for investors. Company leadership projected 2026 revenue between €2 billion and €2.3 billion. This range sits approximately €450 million below the €2.75 billion figure that Wall Street analysts had anticipated at the midpoint.
The primary culprit behind the revenue shortfall is weakening Covid-19 vaccine sales. Company officials indicated that Comirnaty revenue will likely decline throughout 2026 as vaccination demand continues to soften across both American and European territories.
The company’s partnership with Bristol Myers Squibb on cancer immunotherapy development is projected to generate revenue “broadly in line with 2025,” providing minimal support to compensate for declining Covid vaccine sales.
Founding Leadership to Depart This Year
Adding to investor concerns was the leadership announcement. Ugur Sahin, serving as CEO, and Ozlem Tureci, the Chief Medical Officer — who are married and established BioNTech together in 2008 — revealed plans to exit the organization before 2026 concludes to create a new startup centered on mRNA innovation.
The company’s supervisory board has initiated a recruitment process to identify suitable successors.
Management disclosed intentions to transfer “related rights and mRNA technologies” to the founders’ new enterprise in return for a minority ownership position, performance-based milestone payments, and commercial royalty arrangements. Both organizations will maintain independent operations with distinct resource pools and capital structures.
Sahin and Tureci elevated BioNTech to global prominence throughout the Covid-19 health crisis, when their pioneering mRNA research led to the development of the Comirnaty vaccine in collaboration with Pfizer.
Regulatory Headwinds for mRNA Technology
The stock has additionally confronted mounting regulatory challenges within the United States. mRNA vaccine technology has encountered heightened examination since Robert F. Kennedy Jr. assumed leadership of the Department of Health and Human Services. The present administration has demonstrated considerable skepticism toward mRNA vaccination platforms.
Prior to Tuesday’s sharp decline, BNTX had posted a 7.3% gain in 2026. Pfizer, its collaborative partner on Comirnaty, had appreciated 7.7% during the identical timeframe.
For comparison, Moderna had surged 89% and Novavax had climbed 57% entering Tuesday’s session — substantially outperforming their larger industry competitors.
BioNTech’s projected adjusted research and development expenditures for 2026 range between €2.2 billion and €2.5 billion, demonstrating continued commitment to advancing its oncology development pipeline.
Management stated expectations to operate 15 late-stage oncology clinical studies by year’s end, with strategic objectives to transform into a diversified multi-product organization by 2030.
BioNTech’s American depository receipts traded at $84.59 during Tuesday’s premarket session, representing a 17% decline.
